Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral capsule
|
| gptkbp:approves |
gptkb:2019
gptkb:FDA |
| gptkbp:atccode |
C07 BX04
|
| gptkbp:casnumber |
56392-17-7
|
| gptkbp:chemical_formula |
C19 H24 N2 O4 S
|
| gptkbp:clinical_trial |
Phase III trials
|
| gptkbp:contraindication |
hypersensitivity to tafamidis
|
| gptkbp:developed_by |
gptkb:Pfizer
|
| https://www.w3.org/2000/01/rdf-schema#label |
tafamidis meglumine
|
| gptkbp:marketed_as |
gptkb:Vyndaqel
|
| gptkbp:mechanism_of_action |
stabilizes transthyretin protein
|
| gptkbp:side_effect |
fatigue
headache nausea diarrhea |
| gptkbp:used_for |
treatment of transthyretin amyloidosis
|
| gptkbp:bfsParent |
gptkb:Vyndamax
|
| gptkbp:bfsLayer |
8
|